ENSomeone who has been told that their kidneys are failing looks for a way out other than dialysis, comes across the words «stem cells» and finds websites promising a regenerated kidney. That hope is understandable, but stem cell treatment for kidneys in Germany is still research, not routine care.
This page covers what the treatment actually refers to, where the science stands, what German law permits and what a kidney patient is offered there today.
What «stem cells» means in kidney disease
In kidney disease, the cells most often studied are mesenchymal stromal cells (often called mesenchymal stem cells), taken from bone marrow or from fat tissue. They count as stem cells because they can divide and turn into other cell types. The logic under study is not building a new kidney but slowing the inflammation and fibrosis, or scarring, that drive the loss of function.
Many websites blur three things together: blood stem cells in blood diseases, an established treatment with decades of history; mesenchymal cells in kidney disease, which are still research; and vaguely described «cell products» sold by private clinics.
The directions being studied are acute kidney injury after surgery or in intensive care, diabetic kidney disease, chronic fibrosis and protecting a transplanted kidney from rejection. The wider picture is in the article stem cell therapy: what is proven and what is not.
What has been shown and what has not
As things stand, neither Germany nor the European Union has an approved stem cell treatment for kidney disease as routine care. What exists are early-phase clinical trials, mostly small, whose first purpose is to measure safety.
A single headline is not enough. A result in a laboratory animal and a result in a patient are different things, as are a temporary improvement in a blood test and a real delay of dialysis. A randomised controlled trial measures that difference by assigning patients by chance to cell therapy or a comparison and comparing outcomes such as the need for dialysis. A peer-reviewed review of regenerative cell therapies in nephrology sets out how far the field has come from animal studies to patients.
A patient should be wary of a promised outcome, a fixed price quoted before any work-up, a refusal to name the cell product and the protocol in writing, and no follow-up after the procedure.
What German law allows
In Germany a cell product is a medicine, not a «procedure»: it falls under the Medicinal Products Act (Arzneimittelgesetz) and needs authorisation from the Paul Ehrlich Institute. So it cannot be given outside an approved trial or an approved compassionate-use programme, a scheme for seriously ill patients without a satisfactory authorised treatment, simply because a patient is willing to pay.
For a patient travelling in, a university nephrology department may offer a trial place if the criteria fit, but will not sell a stem cell injection on request. That is in the patient’s interest, not against it.
Clinics marketing such injections exist inside and outside Germany, and a German address is no guarantee in itself. To compare for yourself, see is stem cell therapy legal in Germany and stem cell clinics in Germany.
What a kidney patient is actually offered in Germany
A kidney patient in Germany is offered what genuinely changes the course of the disease today: an exact diagnosis of the cause, including a kidney biopsy where needed, control of blood pressure and blood sugar, and drugs with proven slowing of decline. These include ACE inhibitors or angiotensin receptor blockers, SGLT2 inhibitors and, in type 2 diabetes with protein in the urine, non-steroidal mineralocorticoid receptor antagonists. Just as important is a review of every medicine that strains the kidneys.
When kidney function nears its end, the forms of dialysis come in: haemodialysis in a unit, or peritoneal dialysis at home. The vascular access for haemodialysis is prepared well in advance. See dialysis in Germany.
For a suitable patient, a kidney transplant remains the most effective option: compared with dialysis, recipients have lower mortality and a much better quality of life. The conditions are strict: German law allows living donation to a particular patient only from someone close to them, and organ trading is banned. See kidney transplant in Germany. The site’s nephrologists include the director of the III. Medical Clinic at the University Hospital Hamburg-Eppendorf (UKE), Prof. Tobias B. Huber, nephrologist.
Frequently asked questions
Can stem cells repair damaged kidneys?
Not at present: no method has been shown to restore lost kidney function with stem cells. Mesenchymal cells are studied in acute kidney injury, diabetic kidney disease, fibrosis and transplantation, but in early-phase trials whose first aim is safety. No cell therapy for kidney disease is approved in the European Union, so an offer to regenerate a kidney with an injection calls for caution.
Can stem cells help me avoid dialysis?
There is no evidence that they can. Trials have not shown that cell therapy lets patients give up dialysis or reliably postpone it, and a temporary improvement in blood tests is not the same thing. Loss of function is slowed today by control of blood pressure and blood sugar and by drugs with proven effect. When the kidneys fail, a nephrologist discusses dialysis or a transplant.
How can I join a clinical trial for kidney disease?
Through the nephrology department of a university hospital: its doctors review your records and say whether a suitable trial is running and whether you meet its criteria. A genuine trial has a number in a public register such as the EU’s CTIS or ClinicalTrials.gov. Participants generally do not pay for the investigational product, so a request for payment is a warning sign.
How AlenMed handles an enquiry like this
Your laboratory results, discharge summaries and kidney function values go to a nephrology department at a partner hospital, which replies in writing: the diagnosis, what is available and whether a suitable trial exists at all. AlenMed works with 86 partner hospitals in 38 German cities and 345 doctors, and its own office is in Munich. An interpreter attends every appointment, the hospital provides a written estimate, and the company helps with the visa.
AlenMed does not arrange stem cell injections outside authorised settings. Settle in advance who the treating doctor is, what the alternative to the requested method is and how follow-up works at home.
This material is for information only and is not an offer. The treatment plan is decided by a doctor at an in-person consultation.